For example, utilization of a 21-gene assay in breast cancer has the potential to identify a substantial proportion (up to 85%) of women with early hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who may not require adjuvant chemotherapy (4). This evidence concerns the gene NR4A1 and breast cancer.